The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy.
Lars Christian Hanker
Honoraria - Roche
Thomas Hitschold
No relevant relationships to disclose
Tobias Hesse
Honoraria - Roche (B)
Research Funding - Roche
Andrea Grafe
Other Remuneration - Roche
Frank Gerhard Foerster
No relevant relationships to disclose
Jan Klaus Schroeder
No relevant relationships to disclose
Jan Janssen
No relevant relationships to disclose
Dietmar Arno Reichert
No relevant relationships to disclose
Carsten Hielscher
Honoraria - Roche
Research Funding - Roche
Jasmin Greinemann
Employment or Leadership Position - iOMEDICO
David Julian Borquez
No relevant relationships to disclose
Marcus Schmidt
Consultant or Advisory Role - Roche
Stock Ownership - Roche
Honoraria - Roche
Other Remuneration - Roche